Recent News

• 10.06.2025 - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
• 10.06.2025 - KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
• 10.06.2025 - KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
• 10.06.2025 - KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
• 10.03.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.03.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.02.2025 - KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
• 10.02.2025 - KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

Recent Filings

• 10.06.2025 - 8-K Current report
• 10.06.2025 - EX-99.1 EX-99.1
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 8-K Current report
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - EX-99.1 EX-99.1
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities